Skip to main content
OpenTrials
Completed

NCT Number: NCT05589935

Radicle Relief 1: A Study of Health and Wellness Products on Pain and Other Health Outcomes

A randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on pain and other health outcomes

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–105 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radicle Science, Inc

Del Mar, California, 92014, United States

About this study

This is a randomized, blinded, placebo-controlled study conducted with up to 300 adult participants per study arm, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for less pain, (2) indicate an interest in taking a health and wellness product to potentially help relieve their pain, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data are collected electronically from eligible participants over 5 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
  • Resides in the United States
  • Endorses pain as a primary issue (desire for less pain)
  • Selects their desire for less pain and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion criteria

  • Reports being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid physical shipping address
  • Reports a diagnosis of liver or kidney disease
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Lack of reliable daily access to the internet
  • Reports taking anticoagulants, any medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or MAOIs
  • Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection

Treatment and study plan

Relief Study Product Usage

Dietary Supplement

Participants instructed to use study product daily as directed for a period of 4 weeks

Primary outcomes

  1. Change in pain interference

    Time frame: 4 weeks

    Mean difference in pain interference score as assessed by Patient Reported Outcome Measurement System (PROMIS) Pain Interference 6A [scale 6-30; with higher scores corresponding to greater pain interference]

Secondary outcomes

  1. Change in neuropathic pain

    Time frame: 4 weeks

    Mean difference in neuropathic pain score as assessed by PROMIS Neuropathic Pain 5A [scale 5-25; with higher scores corresponding to greater neuropathic pain]

  2. Change in nociceptive pain

    Time frame: 4 weeks

    Mean difference in nociceptive pain score as assessed by PROMIS Nociceptive Pain 5A [scale 5-25; with higher scores corresponding to greater nociceptive pain]

  3. Change in pain intensity

    Time frame: 4 weeks

    Mean difference in pain intensity score as assessed by PROMIS Pain Intensity 1A [scale 1-10; with 0 being 'No pain' and 10 being 'The worst imaginable pain']

  4. Change in feelings of anxiety

    Time frame: 4 weeks

    Mean difference in anxiety score as assessed by PROMIS Anxiety 4A [scale 4-20; with higher scores corresponding to more severe anxiety]

  5. Change in sleep disturbance

    Time frame: 4 weeks

    Mean difference in sleep disturbance score as assessed by PROMIS Sleep Disturbance Form 4A [scale 4-20; with higher scores corresponding to more severe sleep disturbance]

  6. Minimal clinically important difference (MCID) in pain interference

    Time frame: 4 weeks

    Likelihood of experiencing MCID in pain interference score as assessed by PROMIS Pain Interference 6A

  7. Minimal clinically important difference (MCID) in neuropathic pain

    Time frame: 4 weeks

    Likelihood of experiencing MCID in neuropathic pain score as assessed by PROMIS Neuropathic Pain 5A

  8. Minimal clinically important difference (MCID) in nociceptive pain

    Time frame: 4 weeks

    Likelihood of experiencing MCID in nociceptive pain score as assessed by PROMIS Nociceptive Pain 5A

  9. Minimal clinically important difference (MCID) in pain intensity

    Time frame: 4 weeks

    Likelihood of experiencing MCID in pain intensity score as assessed by PROMIS Pain Intensity 1A

Other outcomes

  1. Change in energy (fatigue)

    Time frame: 4 weeks

    Mean difference in fatigue score as assessed by PROMIS Fatigue 4A [scale 4-20; with higher scores corresponding to greater fatigue]

  2. Change in cognitive function

    Time frame: 4 weeks

    Mean difference in cognitive function score as assessed by PROMIS Cognitive Function 4A [scale 4-20; with higher scores corresponding to greater cognitive function]

  3. Change in emotional distress

    Time frame: 4 weeks

    Mean difference in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A [scale 4-20; with higher scores corresponding to greater levels of emotional distress]

  4. Change in sexual interest

    Time frame: 4 weeks

    Mean difference in sexual interest as assessed by PROMIS Sexual Interest 2.0 [scale 2-10; with higher scores corresponding to greater interest in sexual activity]

Sponsors and collaborators

Lead sponsor

Radicle Science

Industry

Registry information

Official study title

Radicle Relief 1™: A Randomized, Blinded, Placebo-Controlled Direct-to-Consumer Study of Health and Wellness Products on Pain and Other Health Outcomes

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Oct 21, 2022
Registry last updated
Nov 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.